Status:
RECRUITING
PIVKA-II for Predicting Portal Vein Thrombosis in Hepatocellular Carcinoma
Lead Sponsor:
Tanta University
Conditions:
Hepato Cellular Carcinoma (HCC)
Portal Vein Tumour Thrombosis
Eligibility:
All Genders
18+ years
Brief Summary
The goal of this cross-sectional observational study is to evaluate the relation between Prothrombin induced by vitamin K absence II (PIVKA-II) and the presence of portal vein tumor thrombosis (PVTT) ...
Eligibility Criteria
Inclusion
- Male or female patients older than 18 years.
- Patients with confirmed HCC with or without PVTT (Diagnosed by two imaging modalities or one imaging modality with elevated serum alpha fetoprotein or liver biopsy).
Exclusion
- Prior locoregional therapy or liver transplantation.
- Patients on vitamin K, vitamin K antagonists or antibiotics.
- Patients with cholestasis.
- Patients with renal insufficiency.
- Patients with other malignancies.
- Unwilling to participate in our study.
Key Trial Info
Start Date :
January 15 2025
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 31 2025
Estimated Enrollment :
116 Patients enrolled
Trial Details
Trial ID
NCT06960954
Start Date
January 15 2025
End Date
December 31 2025
Last Update
May 7 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Tanta University Hospitals
Tanta, Gharbyea, Egypt, 31516